Osteo Arthritis Knee
Conditions
Keywords
Diclofenac, Non-steroidal anti-inflammatory drugs, Physiotherapy, Gonarthrosis
Brief summary
Osteoarthritis, a chronic and degenerative joint disease, is the most common type of arthritis and affects more than 300 million adults worldwide. Osteoarthritis, which is characterized by joint pain and stiffness, has negative consequences for function, participation and quality of life, which are important components of health. The knee joint is the most common joint in terms of osteoarthritis and is more common in individuals over 50 years of age. There is no proven definitive treatment in today's literature for common osteoarthritis, which is one of the important causes of the global disease burden. However, since it is a progressive disease with varying degrees of severity, it is a chronic problem that requires long-term treatment. According to current clinical guidelines prepared by the working groups of the International Osteoarthritis Research Society (OARSI) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases ESCEO , treatment typically includes physiotherapy interventions with the use of non-steroidal anti-inflammatory drugs (NSAIDs) and analgesics, including intra-articular injections of corticosteroids; In more severe cases, joint replacement surgery is recommended. The aim of this research project is to examine the effectiveness of a supervised exercise program applied in combination with NSAID-specific topical agents, in comparison with groups receiving only topical agents or only exercise treatments.
Detailed description
Voluntary participants who have been diagnosed with knee osteoarthritis will be included in the study. Signed voluntary consent will be obtained from participants. Participants will be divided into tree groups. Study groups will be as follows: a) exercise, b) exercise & topical agent, c) topical agent.
Interventions
OTHERExercise
Supervised exercise program with a physiotherapist for 6 weeks, two days a week
OTHERExercise&Topical Agent
Diclofenac gel application to the knee joint twice a day, four days a week, in addition to a supervised exercise program under the supervision of a physiotherapist for 6 weeks.
OTHERTopical Agent
Application of diclofenac gel to the knee joint twice a day, four days a week, for 6 weeks
Sponsors
Istanbul University - Cerrahpasa
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)
Masking description
The assessor will not know which participant received which intervention.
Intervention model description
There will be an equal number of participants in the three groups randomized by the computer.
Eligibility
Sex/Gender
ALL
Age
40 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Diagnosed with knee OA according to the criteria of the American Society of Rheumatology * Stage 2 or 3 according to Kellgren Lawrence radiological staging criteria * Those between the ages of 40 and 65 * Body mass index below 30 kg/m2 * Pain intensity defined by the patient in the last 3 months is at least 3 out of 10 according to NPRS * Patients who do not have any obstacles to be included in the exercise program
Exclusion criteria
* Using viscosupplementation or steroid injection or systemic steroids in the related knee in the last 3 months * To have received a physiotherapy program for the relevant knee in the last 3 months * Having a valgus or varus deformity greater than 15° * Presence of active infection or tumor * Presence of neurological diseases and/or deformity leading to lower extremity muscle weakness * Having serious systemic and cardiovascular diseases that interfere with exercise
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change of Pain via Numeric Pain Rating Scale | change from baseline pain at 6 months | On this scale, 0 indicates the absence of pain, and 10 indicates the most severe pain imaginable (17). Patients will be asked to rate the severity of their knee pain with a number between 0 and 10 using this scale. The minimum clinically significant difference value (MCID) of this valid and reliable pain scale is 1.74 points. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 40 meters fast walking test | 4 times for 24 weeks | For 40mHYT, patients will be asked to walk as fast as possible on a flat and hard surface, on a 10-meter marked walking path. Walking time will be measured in seconds with a stopwatch. The test will be repeated three times and the arithmetic mean of these measurements will be recorded as the result value. Considering the age range of the patients, it was planned to allow a one-minute rest period between retests. |
| Stepping Test | 4 times for 24 weeks | Patients will be asked to climb 10 pre-marked 20 cm high steps as quickly as possible on a standard ladder. The test time will be measured in seconds with a stopwatch. The test will be repeated 3 times and the average value will be recorded in seconds. Similarly, in this evaluation, patients were given a one-minute rest period between 3 repetitions of the test. |
| WOMAC | 4 times for 24 weeks | WOMAC assesses the level of difficulty, pain and joint stiffness experienced by the patients during their physical functions. WOMAC score is a 5-point Likert-type scale, high scores indicate poor status and consist of a total of 24 questions. |
| Health-Related Quality of Life Short Form (SF-12) Scale | 4 times for 24 weeks | SF-12 is the abbreviated version of the SF36 Quality of Life Scale and is frequently preferred for ease of use. It has 2 components, physical and mental, scored between 0 and 50. A high score from the score indicates health-related well-being and increased quality of life, while a decrease indicates worsening. |
| Global Rating of Change Scale-GRC | 3 times for 24 weeks | It will be used to evaluate patient satisfaction. It is designed to determine the amount of improvement or worsening of the patient over time. In our study, GRC consisting of 5 levels between -2 and +2 value ranges (-2: I am much worse, -1: I am worse, 0: I am the same, 1: I am better, 2: I am much better) was preferred. |
| Joint Range of Motion Evaluation | 4 times for 24 weeks | During the assessments, three repeat measurements will be made using an electronic goniometer. For goniometric measurement, the pivot point will be placed on the lateral condyle of the femur. The fixed arm will be held parallel to the lateral midline of the femur. The movable arm will follow the movement of the fibula. |
Countries
Turkey (Türkiye)
Outcome results
None listed